Truist analyst Mark Hughes raised the firm’s price target on Globe Life to $90 from $80 and keeps a Hold rating on the shares. The analyst cites the company’s Q2 earnings beat and guidance raise, with top-line growth driven by Life premium expansion of 4% and Health premium growth of 7%. Truist adds that Globe Life’s Audit Committee determined that the financial misconduct allegations were “not supported”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GL:
- Globe Life attractive risk/reward masked by uncertainty, says JPMorgan
- Globe Life sees fiscal 2024 operating EPS $11.80-$12.10, consensus $11.75
- Globe Life reports Q2 operating EPS $2.97, consensus $2.91
- GLOBE LIFE INC. REPORTS SECOND QUARTER 2024 RESULTS
- Globe Life audit committee finds no merit to short seller claims